Adoprazine (SLV313) exhibits atypical antipsychotic properties; it acts as a potent dopamine D2 and D3 receptor antagonist and a full agonist at the 5-HT1A receptor, demonstrating efficacy in modulating extracellular dopamine and serotonin levels in the nucleus accumbens, suggesting its potential application in the treatment of psychiatric disorders such as schizophrenia.